Verition Fund Management’s Amylyx Pharmaceuticals AMLX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q2
Sell
-75,000
Closed -$213K 2962
2024
Q1
$213K Buy
+75,000
New +$981K ﹤0.01% 2469

Other funds holding AMLX

Verition Fund Management's AMLX Position: Q2 2026 in Review

Verition Fund Management sold out of Amylyx Pharmaceuticals (AMLX) in Q2 2026, closing a stake of 13,264 shares — an estimated $184K sold.

Verition Fund Management first reported a position in AMLX in Q1 2022 and held it in 11 quarters. The position peaked at $18.3M in Q2 2022. 207 funds tracked by Wall St. Rank hold AMLX as of Q2 2026.

  • Verition Fund Management reported no remaining Amylyx Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Verition Fund Management sold 13,264 Amylyx Pharmaceuticals shares in Q2 2026, an estimated $184K.
  • Verition Fund Management first reported a position in Amylyx Pharmaceuticals in Q1 2022 and held it in 11 quarters.
  • Verition Fund Management's Amylyx Pharmaceuticals position peaked at $18.3M in Q2 2022.
  • 207 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2026.

Based on Verition Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.